Clinical trial
A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of ALS
NCT06513546 is registered in ClinicalTrials.gov with PLL TX AUSTRALIA PTY LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of ALS
- Lead sponsor
- PLL TX AUSTRALIA PTY LTD
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- April 8, 2026
- Completion date
- June 15, 2027
- Enrollment
- 153 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.